Sartorius (SARTF) Upgraded to Buy by Zacks Investment Research

Sartorius (OTCMKTS:SARTF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Wednesday. The firm presently has a $150.00 target price on the stock. Zacks Investment Research‘s target price would indicate a potential upside of 11.77% from the stock’s current price.

According to Zacks, “Sartorius AG is a pharmaceutical and laboratory equipment supplier. The company manufactures equipment for biomolecular and microbial separations, cell culture, concentration, fermentation and purification. Sartorius AG is headquartered in Goettingen, Germany. “

Shares of SARTF opened at $134.21 on Wednesday. The company has a market capitalization of $5.02 billion, a PE ratio of 71.77 and a beta of 0.08. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.00 and a current ratio of 1.62. Sartorius has a one year low of $124.00 and a one year high of $149.00.



Sartorius (OTCMKTS:SARTF) last announced its earnings results on Tuesday, October 23rd. The company reported $0.79 EPS for the quarter, topping the consensus estimate of $0.74 by $0.05. The business had revenue of $459.56 million for the quarter, compared to the consensus estimate of $460.00 million. Sartorius had a return on equity of 20.21% and a net margin of 9.09%. On average, sell-side analysts expect that Sartorius will post 2.98 EPS for the current fiscal year.

About Sartorius

There is no company description available for Sartorius AG.

Read More: Return on Equity (ROE)

Get a free copy of the Zacks research report on Sartorius (SARTF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply